Fecal Clostridium symbiosum for Noninvasive Detection of Early and Advanced Colorectal Cancer: Test and Validation Studies

Xie, Yuan; Gao, Qin; Cai, Guo-Jun; Sun, Xiao Ming; Zou, Tian Hui; Chen, Hui Min; Yu, Si Yi; Qiu, Yi Wen; Gu, Wei; Chen, Xiao Yu; Cui, Yun; Sun, Da; Liu, Zhanju; Cai, Sanjun; Xu, Jie; Chen, Ying Xuan; Fang, Jing

doi:10.1016/j.ebiom.2017.10.005

Cited by 139 publications

(138 citation statements)

References 37 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…For cohorts with larger sample size (>200), the diagnostic ability of fecal F. nucleatum for CRC was better than cohorts with smaller sample size, with lower sensitivity. And the heterogeneity of sensitivity, positive DLR, and negative DLR all dropped sharply.…”

Section: Resultsmentioning

confidence: 95%

Fecal Fusobacterium nucleatum for the diagnosis of colorectal tumor: A systematic review and meta‐analysis

et al. 2019

Self Cite

View full text Add to dashboard Cite

The fecal Fusobacterium nucleatum has been reported as a potential noninvasive biomarker for colorectal tumor in several studies, but its exact diagnostic accuracy was ambiguous due to the wide range of sensitivity and specificity. To assess the diagnostic accuracy of fecal F. nucleatum for colorectal tumor, we searched electronic databases including PubMed, Cochrane Library, Embase, and Web of Science, without any date and language restrictions. Two reviewers independently extracted data and appraised study quality with Quality Assessment of Diagnostic Accuracy Studies. We included ten studies comprising 13 cohorts for colorectal cancer (CRC) and seven cohorts for colorectal adenoma (CRA). A total of 1450 patients and 1421 controls for CRC and 656 patients and 827 controls for CRA were included. The pooled sensitivity and specificity of fecal F. nucleatum for CRC were 71% (95% CI, 61%‐79%) and 76% (95% CI, 66%‐84%), with the area under the receiver‐operating characteristics (AUC) curve of 0.80 (95% CI, 0.76‐0.83). The pooled sensitivity and specificity of fecal F. nucleatum for CRA were 36% (95% CI, 27%‐46%) and 73% (95% CI, 65%‐79%), with an AUC of 0.60 (95% CI, 0.56‐0.65). Substantial heterogeneity among studies existed, which was partly caused by DNA extraction kits, regions of study, sample size, and demographic characteristics of participants. Fecal F. nucleatum was valuable for the diagnosis of CRC although it performed below expectation. For CRA, the specificity of fecal F. nucleatum indicated the possibility of noninvasive screening. Subgroup analyses for adenoma were incomplete due to lack of data. Heterogeneity limited the credibility of the study.

show abstract

Section: Resultsmentioning

confidence: 95%

Fecal Fusobacterium nucleatum for the diagnosis of colorectal tumor: A systematic review and meta‐analysis

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…The significant difference in gut microbiota composition between cancer patients and healthy individuals demonstrates diagnostic and prognostic potentials of special microbial pathogens in cancer. For examples, a significant stepwise increase of Fn abundance was found in healthy controls, colorectal adenoma patients and CRC patients, indicating its potential application value in early diagnosis of CRC . Combining the abundance of Fn and fecal immunochemical test could improve the accuracy and sensitivity in diagnosis of CRC and advanced adenoma .…”

Section: Gut Microbiota and Cancermentioning

confidence: 99%

“…67 Combining the abundance of Fn and fecal immunochemical test could improve the accuracy and sensitivity in diagnosis of CRC and advanced adenoma. 67,68 In addition to the diagnostic utility, the amount of Fn in CRC tissue is associated with patient survival. Collectively, a better understanding of how special microbial pathogens elicit specific carcinogenesis may uncover valuable biomarkers for diagnosing and prognosticating cancer.…”

Section: Special Microbial Pathogens In Cancermentioning

confidence: 99%

Fecal microbiota transplantation in cancer management: Current status and perspectives

Chen

Jin

et al. 2018

Intl Journal of Cancer

236

161

View full text Add to dashboard Cite

The human gut is home to a large and diverse microbial community, comprising about 1,000 bacterial species. The gut microbiota exists in a symbiotic relationship with its host, playing a decisive role in the host's nutrition, immunity and metabolism. Accumulating studies have revealed the associations between gut dysbiosis or some special bacteria and various cancers. Emerging data suggest that gut microbiota can modulate the effectiveness of cancer therapies, especially immunotherapy. Manipulating the microbial populations with therapeutic intent has become a hot topic of cancer research, and the most dramatic manipulation of gut microbiota refers to fecal microbiota transplantation (FMT) from healthy individuals to patients. FMT has demonstrated remarkable clinical efficacy against Clostridium difficile infection (CDI) and it is highly recommended for the treatment of recurrent or refractory CDI. Lately, interest is growing in the therapeutic potential of FMT for other diseases, including cancers. We briefly reviewed the current researches about gut microbiota and its link to cancer, and then summarized the recent preclinical and clinical evidence to indicate the potential of FMT in cancer management as well as cancer‐treatment associated complications. We also presented the rationale of FMT for cancer management such as reconstruction of intestinal microbiota, amelioration of bile acid metabolism, and modulation of immunotherapy efficacy. This article would help to better understand this new therapeutic approach for cancer patients by targeting gut microbiota.

show abstract

“…[4][5][6][7] Recent basic research has established a critical function for the intestinal microbiota 8 and specific bacterial species, such as Fusobacterium nucleatum (Fn) [9][10][11] and Peptostreptococcus anaerobius, 12 in promoting colorectal tumourigenesis. Bacteria such as Fn, 13 Clostridium symbiosum 14 and species within the genera Parvimonas, Porphyromonas and Parabacteroides 15 have been shown to be potential markers for the diagnosis of patients with CRC. However, current knowledge on biomarkers for colorectal adenoma detection is limited.…”

Section: Introductionmentioning

confidence: 99%

A novel faecalLachnoclostridiummarker for the non-invasive diagnosis of colorectal adenoma and cancer

Liang

Nakatsu

et al. 2019

Gut

Self Cite

229

206

View full text Add to dashboard Cite

ObjectiveThere is a need for early detection of colorectal cancer (CRC) at precancerous-stage adenoma. Here, we identified novel faecal bacterial markers for diagnosing adenoma.DesignThis study included 1012 subjects (274 CRC, 353 adenoma and 385 controls) from two independent Asian groups. Candidate markers were identified by metagenomics and validated by targeted quantitative PCR.ResultsMetagenomic analysis identified ‘m3’ from a Lachnoclostridium sp., Fusobacterium nucleatum (Fn) and Clostridium hathewayi (Ch) to be significantly enriched in adenoma. Faecal m3 and Fn were significantly increased from normal to adenoma to CRC (p<0.0001, linear trend by one-way ANOVA) in group I (n=698), which was further confirmed in group II (n=313; p<0.0001). Faecal m3 may perform better than Fn in distinguishing adenoma from controls (areas under the receiver operating characteristic curve (AUROCs) m3=0.675 vs Fn=0.620, p=0.09), while Fn performed better in diagnosing CRC (AUROCs Fn=0.862 vs m3=0.741, p<0.0001). At 78.5% specificity, m3 and Fn showed sensitivities of 48.3% and 33.8% for adenoma, and 62.1% and 77.8% for CRC, respectively. In a subgroup tested with faecal immunochemical test (FIT; n=642), m3 performed better than FIT in detecting adenoma (sensitivities for non-advanced and advanced adenomas of 44.2% and 50.8% by m3 (specificity=79.6%) vs 0% and 16.1% by FIT (specificity=98.5%)). Combining with FIT improved sensitivity of m3 for advanced adenoma to 56.8%. The combination of m3 with Fn, Ch, Bacteroides clarus and FIT performed best for diagnosing CRC (specificity=81.2% and sensitivity=93.8%).ConclusionThis study identifies a novel bacterial marker m3 for the non-invasive diagnosis of colorectal adenoma.

show abstract

Fecal Clostridium symbiosum for Noninvasive Detection of Early and Advanced Colorectal Cancer: Test and Validation Studies

Cited by 139 publications

References 37 publications

Fecal Fusobacterium nucleatum for the diagnosis of colorectal tumor: A systematic review and meta‐analysis

Fecal Fusobacterium nucleatum for the diagnosis of colorectal tumor: A systematic review and meta‐analysis

Fecal microbiota transplantation in cancer management: Current status and perspectives

A novel faecalLachnoclostridiummarker for the non-invasive diagnosis of colorectal adenoma and cancer

Contact Info

Product

Resources

About